Clinical Trials
8 trialsNCT02495103 2021-01-26
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00514046 2020-12-22
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02015065 2020-03-30
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00923247 2018-11-29
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00566995 2018-10-30
Phase II Study of Vandetanib in Individuals With Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00995007 2016-03-29
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01372813 2015-10-23
Vandetanib to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00445549 2012-06-26
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated